跳轉至內容
Merck
  • Direct reprogramming of cardiomyocytes into cardiac Purkinje-like cells.

Direct reprogramming of cardiomyocytes into cardiac Purkinje-like cells.

iScience (2022-11-18)
Nicole Prodan, Faheem Ershad, Arfaxad Reyes-Alcaraz, Luge Li, Brandon Mistretta, Lei Gonzalez, Zhoulyu Rao, Cunjiang Yu, Preethi H Gunaratne, Na Li, Robert J Schwartz, Bradley K McConnell
摘要

Currently, there are no treatments that ameliorate cardiac cell death, the underlying basis of cardiovascular disease. An unexplored cell type in cardiac regeneration is cardiac Purkinje cells; specialized cells from the cardiac conduction system (CCS) responsible for propagating electrical signals. Purkinje cells have tremendous potential as a regenerative treatment because they may intrinsically integrate with the CCS of a recipient myocardium, resulting in more efficient electrical conduction in diseased hearts. This study is the first to demonstrate an effective protocol for the direct reprogramming of human cardiomyocytes into cardiac Purkinje-like cells using small molecules. The cells generated were genetically and functionally similar to native cardiac Purkinje cells, where expression of key cardiac Purkinje genes such as CNTN2, ETV1, PCP4, IRX3, SCN5a, HCN2 and the conduction of electrical signals with increased velocity was observed. This study may help to advance the quest to finding an optimized cell therapy for heart regeneration.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
纤维蛋白原 来源于牛血浆, Type I-S, 65-85% protein (≥75% of protein is clottable)
Sigma-Aldrich
木瓜蛋白酶 来源于番木瓜, solution, light brown, ≥10 U/mg protein (~25 mg/ml)
Sigma-Aldrich
AC16 人心肌细胞细胞系, AC16 Human Cardiomyocytes can be serially passaged and can differentiate when cultured in mitogen-free medium. The cells may be used to study developmental regulation of cardiomyocytes.
Sigma-Aldrich
TGF-β RI激酶抑制剂VI,SB431542, InSolution, ≥97%
Sigma-Aldrich
GSK-3抑制剂XVI,CHIR99021, InSolution, ≥95%, 25 mM